DIACURIMAP PLUS 10/5MG 30TAB

DIACURIMAP PLUS 10/5MG 30TAB

Description:

DIACURIMAP PLUS 10/5mg 30 tablets is a prescription oral anti-diabetic medicine that combines two modern agents: empagliflozin (an SGLT2 inhibitor) and linagliptin (a DPP-4 inhibitor). It is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. By targeting different mechanisms involved in blood glucose regulation, DIACURIMAP PLUS helps lower fasting and post‑meal blood sugar and supports long-term diabetes management.

Indications:

• Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• For patients in whom treatment with both empagliflozin and linagliptin is considered appropriate by the treating physician.
• Helps reduce elevated fasting blood glucose levels.
• Helps control postprandial (after-meal) blood glucose spikes.
• May be used in patients insufficiently controlled on other anti-diabetic therapies, according to physician judgment and local guidelines.

Active Ingredients / Key Components:

• Empagliflozin – 10 mg per film-coated tablet (sodium-glucose co-transporter 2 (SGLT2) inhibitor).
• Linagliptin – 5 mg per film-coated tablet (dipeptidyl peptidase-4 (DPP-4) inhibitor).
• Other excipients: Full list of inactive ingredients is not available in the provided information; please refer to the official package leaflet for complete composition.

Dosage & Administration / How to Use:

• Recommended adult dose: 1 tablet of DIACURIMAP PLUS 10/5mg taken orally once daily in the morning.
• Tablets may be taken with or without food, swallowed whole with a sufficient amount of water.
• If additional glycemic control is needed and the patient tolerates therapy, the dose may be increased (according to the product range) up to 25 mg empagliflozin / 5 mg linagliptin once daily, as directed by the physician.
• Take the medicine at the same time each day to support consistent blood glucose control.
• If a dose is missed, take it as soon as you remember on the same day. If it is almost time for the next dose, skip the missed dose and resume your usual schedule. Do not double the dose.
• Use only under medical supervision and exactly as prescribed by your doctor, especially if used in combination with other anti-diabetic medicines such as insulin or sulfonylureas.

Clinical Benefits:

• Dual mechanism of action: combines SGLT2 inhibition (increasing urinary glucose excretion) with DPP-4 inhibition (enhancing incretin hormones), providing comprehensive blood glucose control.
• Helps lower fasting and postprandial blood glucose levels in adults with type 2 diabetes.
• May contribute to modest weight reduction due to increased glucose excretion via the kidneys (effect of empagliflozin).
• Low intrinsic risk of hypoglycemia when used without insulin or sulfonylureas, compared with some older anti-diabetic agents.
• Once-daily tablet regimen supports better adherence and long-term diabetes management.

Warnings & Contraindications:

• Contraindicated in patients with known hypersensitivity to empagliflozin, linagliptin, or any component of the formulation.
• Not indicated for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
• Use with caution in patients with impaired renal function; dose adjustment or discontinuation may be required according to kidney function and local prescribing information.
• Risk of volume depletion and hypotension, especially in elderly patients, those on diuretics, or with low blood pressure; monitor hydration status.
• Empagliflozin may increase the risk of genital mycotic infections and urinary tract infections; advise patients on genital hygiene and to report symptoms promptly.
• DPP-4 inhibitors, including linagliptin, have been associated rarely with pancreatitis; discontinue and seek medical attention if persistent severe abdominal pain occurs.
• Use with caution in patients with a history of pancreatitis, severe hepatic impairment, or cardiovascular disease; follow physician guidance.
• Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding; safety in pregnancy and lactation has not been established.
• Consult your doctor before use if you are taking diuretics, blood pressure medicines, insulin, sulfonylureas, or other anti-diabetic agents, or if you have kidney disease, liver disease, cardiovascular disease, recurrent urinary tract infections, or low blood pressure.
• Not intended to diagnose, treat, cure, or prevent any disease without a doctor’s supervision; this is a prescription-only medicine and must be used under medical guidance.
• Keep out of reach of children.

Side Effects:

• Common side effects may include increased urination, urinary tract infections, genital yeast infections, thirst, and mild dehydration symptoms (dizziness, lightheadedness), especially at treatment initiation.
• Gastrointestinal symptoms such as nausea, diarrhea, or abdominal discomfort may occur in some patients.
• Hypoglycemia (low blood sugar) is more likely when DIACURIMAP PLUS is used together with insulin or sulfonylureas; symptoms include sweating, tremor, hunger, confusion, or palpitations.
• Rare but serious adverse effects may include ketoacidosis, severe urinary tract infections, Fournier’s gangrene (necrotizing fasciitis of the perineum), and pancreatitis. Seek immediate medical attention if you experience severe abdominal pain, difficulty breathing, confusion, unusual fatigue, or fever with pain, redness, or swelling in the genital/anal area.
• If any side effects are severe, persistent, or you notice any unusual symptoms, contact your doctor or pharmacist promptly.

Storage Instructions:

Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children. Do not use after the expiry date printed on the pack. Store at or below the temperature specified in the official package leaflet (exact temperature range is not available in the provided information).

Specifications:

• Form: Film-coated tablets.
• Strength: 10 mg empagliflozin / 5 mg linagliptin per tablet.
• Pack size: 30 tablets per pack.
• Intended use: Prescription anti-diabetic medicine for adults with type 2 diabetes mellitus.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.